arrow

From NeuroLex

Jump to: navigation, search



Mivacurium

Name: Mivacurium
Description: Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. Pharmacology: Mivacurium is a short-acting, nondepolarizing skeletal neuromuscular blocking agent which is hydrolyzed by plasma cholinesterase. Mivacurium results in a blockade of neuromuscular transmission by binding competitively with cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine. The neuromuscular block produced by mivacurium is readily antagonized by anticholinesterase agents. The deeper the level of neuromuscular block at reversal, the longer the time required for recovery of neuromuscular function and the greater the dose of anticholinesterase agent required. Because spontaneous recovery after mivacurium is rapid, routine reversal may not always result in a clinical benefit. Mechanism of action: Mivacurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. Drug type: Approved. Small Molecule. Drug category: Neuromuscular Nondepolarizing Agents
Synonym(s): Mivacron
Has role: Drug
Super-category: Molecular entity
URL: http://www.drugbank.ca/drugs/DB01226
Id: DB01226
Related to: Cholinergic system, Muscarinic acetylcholine receptor M2, Neuronal acetylcholine receptor subunit alpha-2
Link to OWL / RDF: Download this content as OWL/RDF


Contributors

Ayeliset, Ccdbuser, Nifbot2



bookmark
Facts about MivacuriumRDF feed
Commenttaken from DrugBank
CurationStatusuncurated  +
CuratorAb  +
DefiningCitationhttp://www.drugbank.ca/drugs/DB01226  +
DefinitionMivacurium is a bisbenzylisoquinolinium ba Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. Pharmacology: Mivacurium is a short-acting, nondepolarizing skeletal neuromuscular blocking agent which is hydrolyzed by plasma cholinesterase. Mivacurium results in a blockade of neuromuscular transmission by binding competitively with cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine. The neuromuscular block produced by mivacurium is readily antagonized by anticholinesterase agents. The deeper the level of neuromuscular block at reversal, the longer the time required for recovery of neuromuscular function and the greater the dose of anticholinesterase agent required. Because spontaneous recovery after mivacurium is rapid, routine reversal may not always result in a clinical benefit. Mechanism of action: Mivacurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. Drug type: Approved. Small Molecule. Drug category: Neuromuscular Nondepolarizing Agents gory: Neuromuscular Nondepolarizing Agents
Has roleDrug  +
IdDB01226  +
LabelMivacurium  +
ModifiedDate14 April 2014  +
RelatedToCholinergic system  +, Muscarinic acetylcholine receptor M2  +, and Neuronal acetylcholine receptor subunit alpha-2  +
SuperCategoryMolecular entity  +
SynonymMivacron  +